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Abstract
Background The systemic immune-inflammation index based on peripheral neutrophil, lymphocyte, and platelet counts has
shown a prognostic impact in several malignancies. The aim of this study was to determine the prognostic role of systemic
immune-inflammation index in patients with pancreatic ductal adenocarcinoma undergoing resection.
Methods Consecutive patients who underwent surgical resection at the department of surgery at the Medical University of
Vienna between 1995 and 2014 were included into this study. The systemic immune-inflammation index was calculated by
the formula platelet*neutrophil/lymphocyte. Optimal cutoffs were determined using Youden’s index. Uni- and multivariate
analyses were calculated by the Cox proportional hazard regression model for overall survival.
Results Three hundred twenty-one patients were included in this study. Clinical data was achieved from a prospective patient
database. In univariate survival analysis, elevated systemic immune-inflammation index was found to be significantly associated
with shortened patients’ overall survival (p = 0.007). In multivariate survival analysis, systemic immune-inflammation index
remained an independent prognostic factor for overall survival (p = 0.004). No statistical significance could be found for platelet
to lymphocyte ratio and neutrophil to lymphocyte ratio in multivariate analysis. Furthermore, area under the curve analysis
showed a higher prognostic significance for systemic immune-inflammation index, compared to platelet to lymphocyte ratio and
neutrophil to lymphocyte ratio.
Conclusion A high systemic immune-inflammation index is an independent, preoperative available prognostic factor in patients
with resectable pancreatic ductal adenocarcinoma and is superior to platelet to lymphocyte ratio and neutrophil to lymphocyte
ratio for predicting overall survival in pancreatic ductal adenocarcinoma patients.
Keywords Pancreatic ductal adenocarcinoma . Systemic immune-inflammation index . Inflammation
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the ninth most
common malignancy and ranks fifth place of cancer-related
death in western countries with inclining incidence.1 Despite
the development of multimodal approaches, combining surgi-
cal resection with perioperative chemo-(radio)therapy, 5-year
survival rate for patients diagnosed with PADC remains poor
with less than 5%.2
Inflammation, as one of the hallmarks of cancer, is an ac-
knowledged factor in tumor biology.3,4 Inflammation-driven
tumorigenesis and tumor progression plays a crucial role in
malignant diseases.3,5 Systemic inflammatory response (SIR)
in the context of tumor-associated inflammation has been
demonstrated to diminish outcome and be of major prognostic
importance in various cancers.6,7 A number of promising and
potentially prognostic immunologic and histologic bio-
markers have been investigated in PDAC.8,9 However, evalu-
ation of these biomarkers is often expensive and time-consum-
ing. Thus, investigation of tumor-driving inflammation-based
components is of major importance and targeting pathways of
inflammatory response might become a cornerstone of cancer
treatment.10 In PDAC, outcome prediction mainly depends on
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clinical and pathological factors, such as tumor size, lymph
node involvement, and distant metastases as well as resection
margin.11 Notably, these factors are obtained post-operatively
through evaluation of the surgical specimen and current avail-
able prognostic markers do not allow to preoperatively predict
outcome. Therefore, identification of easy-available markers
might help to determine individual treatment approaches. The
utility of inflammation-based scores, such as neutrophil-
lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR)
and systemic immune-inflammation index (SII), are based
on routinely obtained markers that are available before sur-
gery. Elevated SII has been reported to be associated with
clinico-pathological parameters and has been proven to be
an independent prognostic factor in a number of malignancies,
including PDAC.12–16 However, no data exists until now, de-
scribing the prognostic value of the SII in PDAC after neoad-
juvant treatment. The aim of the present study was to assess
the prognostic value of SII in patients undergoing a potentially
curative resection for PDACwith or without neoadjuvant ther-
apy. Furthermore, the SII is compared with NLR and PLR in
predicting survival in this cohort of patients.
Material and Methods
Patients undergoing resection for PDAC between 1995 and
2014 at the Department of Surgery, Medical University of
Vienna, were identified from a prospectively maintained
PDAC database. Both patients who primarily underwent
surgery and patients with borderline resectable disease ac-
cording to NCCN guidelines who were treated by chemo-
therapy or radio-chemotherapy before resection were
included.17 The study was approved by the Ethics
Committee of the Medical University Vienna, Austria, in
accordance with the Helsinki declaration (EK 1166/2013).
Clinico-pathological data were assembled from medical re-
cords, including, gender, age, preoperative neutrophil,
lymphocyte and platelet counts, tumor site, histopatholog-
ical tumor grading, staging (TNM) according to the 8th
edition of the Union for International Cancer Control
(UICC)/American Joint Committee on Cancer (AJCC),
neoadjuvant treatment and surgical resection technique.
Tumor resection margin status (R) was classified as R0 or
R1 (1-mm tumor-free margin). Patients with distant metas-
tases at time of diagnosis and death from other cause within
30 days post-surgery as well as patients who had recently
pyrexia (axillary ≥ 37.2 °C/99.0 °F), any form of active
infection or chronic inflammatory disease were excluded
from the study. Each patient was discussed in the multidis-
ciplinary team meeting before surgery. Neo-/adjuvant che-
motherapy was administered according to the standard reg-
imens available at the respective period. For neoadjuvant
treatment, 5-fluorouracil was used from 1995 to 1998,
whereas gemcitabine-based regimens (gemcitabine
monotherapy and combinations with oxaliplatin, erlotinib,
and nab-Paclitaxel) or FOLFIRINOX were used from 1999
onwards. The present standard for neoadjuvant treatment
since several years consists of either FOLFIRINOX or
Gem/nab-Pac depending on patients’ condition. For adju-
vant chemotherapy, 5-fluorouracil-based regimens were
used between 1995 and 1998 and gemcitabine-based regi-
mens were administered thereafter. All patients were regu-
larly followed thereafter with physical examination, tumor
marker, and computed tomographic scan every 3 months
for the first 2 years and every 6 months until 5 years after
surgery.
Blood samples were obtained within 7 days prior to sur-
gery. NLR, PLR, and SII were calculated as previously de-
scribed: NLR = neutrophils / lymphocytes, PLR = platelet /
lymphocy tes , and SI I = p la te l e t s × neu t roph i l s /
lymphocytes.16
Statistical Analysis
Statistical analysis was performed using the R statistical
software (Version 3.4.3) with the BSurvival,^ BpROC,^
and BOptimal Cutpoints^ packages.18–21 To evaluate the
discriminatory ability of the SII, NLR, and PLR, ROC
curves were generated and the area under the ROC curves
(AUROCs) was measured and compared. For bivariate
analysis, to investigate relationships between SII, NLR,
and PLR and clinico-pathological parameters, t test and
the Wilcoxon test were used as appropriate. Univariate
and multivariate analyses were conducted using the Cox
proportional hazard model. In the multivariable model,
SII, NLR, and PLR could not be included into together,
due to multicollinearity. Therefore, the stepwise regres-
sion analysis for multivariate Cox models, SII, NLR,
and PLR could not be included into the model together
due to multicollinearity. Discrimination ability was com-
pared using the receiver operating curve. Optimal cutoff
values for SII, NLR, and PLR were determined using
Youden’s index, which maximizes the sum of sensitivity
and specificity. Graphically, it is represented by the dis-
tance between the 45-degree line and the ROC22,23. The
graphical analysis was performed using the Kaplan-Meier
survival curve estimator and analyzed by the log-rank test.
Overall survival (OS) was defined as time between prima-
ry surgery and the patients’ death. Death from other cause
than PDAC or survival until the end of the observation
period was considered as censored observations. Disease-
free survival (DFS) was defined from the day of surgery
until first evidence of disease progression. Categorical da-
ta was analyzed using the chi-squared test. Continuous
data was either analyzed using the t test form normally
distributed values or the Wilcoxon rank-sum test.
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Table 1 Association of the SII with clinico-pathological parameters in pancreatic ductal adenocarcinoma
Factors All SII
High (≥ 873) Low (< 873) p value
n 324 120 204
Age, mean (SD) 68.25 (9.74) 68.81 (9.21) 67.91 (10.04) > 0.1(*)
Sex > 0.1
Male 169 52.16% 65 104
Female 155 47.84% 55 100
(y)pT > 0.1
0 2 0.62% 1 1
1 24 7.41% 5 19
2 47 14.51% 18 29
3 234 72.22% 87 147
4 17 5.25% 9 8
(y)pN > 0.1
0 86 26.54% 27 59
1 238 73.46% 93 145
(y)G > 0.1
1 15 4.63% 4 11
2 204 62.96% 72 132
3 105 32.41% 44 61
R 0.027
0 254 78.40% 86 168
1 70 21.60% 34 36
UICC staging > 0.1
I 41 12.65% 15 26
II 265 81.79% 96 169
III 18 5.56% 10 8
Neoadjuvant treatment > 0.1
yes 43 13.27% 14 29
no 281 86.73% 106 175
Jaundice 0.041
No 163 50.31% 51 112
Yes 161 49.69% 69 92
CA 19-9 0.013
Unknown 24 7.41% 9 15
≤ 114 kU/L 143 44.14% 42 101
> 114 kU/L 157 48.46% 69 88
Lymph node-ratio > 0.1
Unknown 23 7.10% 7 16
≤ 0.2 196 60.49% 71 125
> 0.2 105 32.41% 42 63
Nicotine > 0.1
Unknown 3 0.93% 1 2
Yes 135 41.67% 55 80
No 186 57.41% 64 122
Pain > 0.1
Yes 130 40.12% 45 85
No 194 59.88% 75 119
Pancreatitis > 0.1
Yes 63 19.44% 20 43
No 261 80.56% 100 161
Diabetes > 0.1
Unknown 12 3.70% 3 9
Yes 73 22.53% 29 44
No 239 73.77% 88 151
Stent > 0.1
Yes 153 47.22% 60 93
No 171 52.78% 60 111
Surgical procedure 0.0345
PPPD 181 55.86% 65 116
Whipple 71 21.91% 35 36
Distal resection 60 18.52% 15 45
Total pancreatectomy 12 3.70% 5 7
Localization > 0.1
1 255 78.70% 100 155
2 24 7.41% 8 16
3 45 13.89% 12 33
(*) Using t test
SD, standard deviation; UICC, Union for International Cancer Control; SII, systemic immune-inflammation index
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Results
In the present study, a total of 321 patients (169, 52.2% male)
with a median age of 68.5 (range, 35.9–92.3) years were in-
cluded. Themajority of patients (201, 62.6%) presented with a
moderately differentiated tumor (G2) and 43 (13.3%) patients
received neoadjuvant treatment prior to resection. In 255
(78.7%) cases, the tumor was located in the head of the pan-
creas and in 238 (73.5%) positive lymph node was found at
pathological assessment. In accordance with the 8th edition
UICC/AJCC classification, 265 (82.6%) patients showed
stage II disease and 153 (47.2%) patients underwent biliary
drainage preoperatively. Clinico-pathological data are present-
ed in Table 1.
The median OS was 18.5 months (range, 1.5–
198 months) and the rate of 3- and 5-year OS was
25.63% and 8.44%, respectively. The optimal cutoff
values for SII, PLR, and NLR were 873, 179, and 225,
respectively. With the defined cutoffs, 119 patients had
SII ≥ 873, 125 patients had PLR ≥ 179, and 225 patients
NLR ≥ 2.15 before surgery. Using bivariate analysis, sig-
nificant relationship between elevated SII and clinico-
pathological parameters was found for resection margin
(p = 0.03), jaundice (p = 0.04), CA 19–9 (p = 0.01), and
surgical procedure (p = 0.04) (Table 1). The median OS
for patients with high SII was 14.2 (range, 1.5–128.2)
months and 20.5 (range, 1.6–200.8) months for patients
with low SII respectively. In the entire cohort, using
overall survival as an end-point, the area under the re-
ceiver operator curve was 0.46 (CI, 0.37–0.55) for SII,
0.46 (CI, 0.36–0.56) for NLR, and 0.51 (CI, 0.42–0.61)
for PLR with no significant difference in discrimination
ability between SII, NLR, and PLR regarding OS was
found (Fig. 1).
Kaplan-Meier curve survival analysis for all patients re-
vealed that low SII (p = 0.004) and PLR (p = 0.04) were sig-
nificantly associated with longer OS, whereas no significance
was found for NLR (Fig. 2).
Univariate Cox proportional hazard regression revealed
that SII, PLR, age, jaundice, resection margin, CA 19-9,
lymph node-ratio, and tumor size were significantly associat-
ed with OS. Similarly, age, jaundice, lymph node-ratio, and
tumor size are significantly associated with DFS whereas SII,
NLR, and PLR was not (Table 2).
Furthermore, no statistical significance was found for OS and
DFS in univariate Cox proportional hazard regression for neoad-
juvant treatment (p = 0.08; RR, 1.35; CI, 95 0.96–1.88; and p=
0.23; RR, 1.24; CI, 95 0.87–1.77; respectively; Table 2).
Multivariate Cox-regression analysis using SII as bi-
variate variable revealed that a high SII (p = 0.016; RR,
a
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Fig. 1 Receiver operating characteristic (ROC) curves were generated to
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Fig. 2 Kaplan-Meier curves for overall survival (OS) stratified by SII (a), NLR (b) and PLR (c)
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0.71; CI, 95% 0.54–0.94), positive resection margin (p =
0.03; RR, 1.46; CI, 95% 1.05–2.03), and a high lymph
node-ratio (p < 0.001; RR, 1.77; CI, 95% 1.32–2.36), but
not NLR and PLR, are independent risk factors for OS
(Table 3). No statistical significant association could be
found for SII, NLR, and PLR in the multivariate Cox
models for DSF (Table 4).
Discussion
Inflammation plays a key role in tumor initiation, malignant
conversion, and metastasis and influences the host anti-tumor
immunity.3–5 The present study investigated the clinical and
prognostic value of preoperative SII, NLR, and PLR in pa-
tients with PDAC undergoing resection and competed their
Table 2 Univariate Cox regression analysis estimating the influence of the SII, NLR, PLR and clinico-pathological parameters on overall survival and
disease-free survival in patients with ductal adenocarcinoma of the pancreas
Overall survival Disease-free survival
RR CI (95%) p value RR CI (95%) p value
SII
≥ 873 vs. < 873 0.6979 0.5469–0.8907 0.0038 0.8147 0.6288–1.0556 0.1211
NLR
≥ 2.15 vs. < 2.15 0.7852 0.6054–1.0184 0.0683 0.8536 0.6455–1.1286 0.2666
PLR
≥ 179 vs. < 179 0.772 0.6031–0.9882 0.0399 0.808 0.6205–1.0522 0.1136
UICC stage
II vs. I 1.0668 0.7438–1.5301 0.7252 1.1808 0.7898–1.7653 0.4179
III vs. I 1.4071 0.7658–2.5852 0.2712 1.2352 0.6366–2.3964 0.5323
Grading
2 vs. 1 0.7087 0.4174–1.2032 0.2023 0.6882 0.3973–1.1922 0.1826
3 vs. 1 1.0347 0.5996–1.7855 0.9026 1.0086 0.5719–1.7785 0.9765
Sex
Male vs. female 1.0843 0.8562–1.373 0.5019 1.0475 0.8145–1.3472 0.7175
Age 0.9881 0.9769–0.9993 0.038 0.9838 0.9714–0.9964 0.0116
Jaundice
Yes vs. no 1.4243 1.1246–1.8039 0.0033 1.4186 1.1013–1.8272 0.0068
R
1 vs. 0 1.4382 1.0866–1.9037 0.0111 1.3526 0.9989–1.8315 0.0508
CA 19-9
≥ 114 vs. < 114 kU/L 1.3148 1.0281–1.6815 0.0292 1.2842 0.9899–1.6661 0.0596
Lymph node-ratio
≥ 0.2 vs. < 0.2 1.8094 1.4006–2.3375 < 0.0001 1.6615 1.264–2.184 0.0003
T-staging
1 vs. 0 0.2554 0.0592–1.1006 0.067 0.1249 0.0162–0.9622 0.0458
2 vs. 0 0.231 0.0553–0.9647 0.0445 0.1209 0.0162–0.9034 0.0395
3 vs. 0 0.2674 0.0657–1.0876 0.0654 0.1266 0.0173–0.9263 0.0418
4 vs. 0 0.3471 0.0786–1.5319 0.1624 0.1349 0.0172–1.0561 0.0564
N-staging
1 vs. 0 1.158 0.8836–1.5176 0.2876 1.0838 0.8162–1.4391 0.5781
Pain
Yes vs. no 0.9929 0.7804–1.2632 0.9535 1.0445 0.8088–1.3488 0.7388
Pancreatitis
Yes vs. no 0.9514 0.7064–1.2815 0.7431 0.8858 0.6426–1.2212 0.4592
Nicotine
Yes vs. no 1.106 0.8705–1.406 0.409 1.0901 0.8457–1.4052 0.5053
Diabetes
Yes vs. no 1.136 0.8545–1.51 0.38 1.1107 0.8214–1.502 0.4953
Neoadjuvant treatment
Yes vs. no 1.3449 0.9616–1.881 0.0834 1.2416 0.8711–1.7696 0.2314
Stent
Yes vs. no 1.1175 0.883–1.4142 0.3553 1.1664 0.9076–1.4989 0.2291
Surgical procedure
PPPD
Whipple 1.0712 0.7961–1.4414 0.6497 1.0691 0.7808–1.4638 0.6769
Distal resection 0.8498 0.6152–1.1739 0.3236 1.2939 0.6334–2.6432 0.4796
Total pancreatectomy 1.4092 0.7425–2.6747 0.294 0.9609 0.6824–1.353 0.8192
Localization
2 vs. 1 0.8828 0.5386–1.4469 0.621 1.0087 0.6055–1.6802 0.9736
3 vs. 1 0.9289 0.6605–1.3062 0.6714 1.0415 0.7199–1.5069 0.829
UICC, Union for International Cancer Control; CI, confidence interval; RR, relative risk; Ref., reference; SII, systemic immune-inflammation index;
PLR, platelet lymphocyte ratio; NLR, neutrophil lymphocyte ratio; PPPD, pylorus-preserving pancreaticoduodenectomy
J Gastrointest Surg
predictive accuracy. Overall, SII, but not NLR and PLR was
an independent prognostic factor for OS in patients with
PDAC undergoing resection.
The relationship between tumor and inflammation was first
described by Virchow in 1863, and later in 1986 by Dvorak as
BTumors: Wounds that do not heal.^ Meanwhile, inflamma-
tion is known as one of the hallmarks of cancer.4,24,25
Increasing data shows the close relationship between tumori-
genesis, tumor progression, and metastasis.4–6 The major
prognostic impact of inflammatory markers can be ascribed
to a cytokine-driven immunogenic tumor microenvironment
and a significant prognostic role of inflammation-based bio-
markers and scores has recently been shown in a number of
malignant diseases.5,7,26–28 One of the newly emerging prog-
nostic scores is the SII, based on platelets, neutrophils, and
lymphocytes. As a combination of both NLR and PLR, SII
firstly has been confirmed as superior prognostic factor in
hepatocellular carcinoma and then in small cell lung cancer
reflecting patient’s inflammatory status.15,16 In a number of
malignancies, including PDAC, an elevated preoperative SII
plays a key role in prognosis estimation.12–16,29–31 This is the
first study that has proven the prognostic value of the SII and
is superior to PLR.
It has been proposed that SII is able to predict tumor recur-
rence in a highly inflammatory tumor microenvironment with
infiltrating immune cells that promote tumorigenesis and
dissemination.5,32 Neutrophils activate endothelium and pa-
renchymal cells via secretion of soluble factors that enhance
tumor cell adhesion at distant sites.33–35 Increasing numbers of
blood neutrophils and platelets have been associated with tu-
mor progression and diminished clinical outcome in a number
of solid tumors.36,37 Lymphocytes inhibit tumor cell prolifer-
ation and migration through induction of cytotoxic cell death
and thus play a key role in cancer immuno-surveillance.5 On
the basis of these findings, several inflammation-based scores
have emerged as prognostic indicators in cancer patients.
Recently published data is diverging regarding the prog-
nostic value of NLR and PLR. The NLR, combining circulat-
ing neutrophil and lymphocyte counts, and the PLR, combin-
ing circulating platelets and lymphocyte counts, has been as-
sociated with impaired survival in lung and ovarian cancers,
while in PDAC results remain inconsistent.38–42 Whereas
Mowbray et al. found preoperative NLR to be an independent
prognostic predictor, Chawla et al. reports that neither NLR
nor PLR predicts survival in patients who underwent pancre-
atectomy for PDAC.43,44
A high SII, consisting of high neutrophil and platelet as
well as low lymphocyte counts, indicates inflammation ac-
tivity that may be associated with poor survival through
enhanced tumor invasion and metastases. Investigating
Table 3 Multivariate Cox regression analysis estimating the influence
of the SII and clinico-pathological parameters on overall survival in pa-
tients with ductal adenocarcinoma of the pancreas
Overall survival SII
RR CI (95%) p value
SII
≥ 873 vs. < 873 0.7138 0.5427–0.9388 0.0159
UICC stage
II vs. I 0.7796 0.493–1.2329 0.2871
III vs. I 0.9423 0.4591–1.9344 0.8714
Grading
2 vs. 1 0.5881 0.3181–1.0875 0.0906
3 vs. 1 0.8104 0.4285–1.5328 0.5179
Sex
Male vs. female 0.9328 0.7155–1.2162 0.6074
Age 0.9874 0.9749–1.0001 0.0514
Jaundice
Yes vs. no 1.1994 0.9094–1.5819 0.1979
R
1 vs. 0 1.4561 1.0457–2.0275 0.0261
CA 19-9
≥ 114 vs. < 114 kU/L 1.1642 0.8795–1.541 0.288
Lymph node-ratio
≥ 0.2 vs. < 0.2 1.7687 1.3247–2.3615 < 0.001
UICC, Union for International Cancer Control; CI, confidence interval;
RR, relative risk; SII, systemic immune-inflammation index
Table 4 Multivariate Cox regression analysis estimating the influence
of the SII and clinico-pathological parameters on disease-free survival in
patients with ductal adenocarcinoma of the pancreas
Disease-free survival SII
RR CI (95%) p value
SII
≥ 873 vs. < 873 0.787 0.5885–1.0524 0.1062
UICC stage
II vs. I 1.0855 0.6388–1.8446 0.7617
III vs. I 1.0861 0.495–2.3831 0.8367
Grading
2 vs. 1 0.5279 0.2826–0.9861 0.0451
3 vs. 1 0.7407 0.3878–1.4148 0.3633
Sex
Male vs. female 0.9176 0.6892–1.2217 0.5562
Age 0.9823 0.9685–0.9964 0.0138
Jaundice
Yes vs. no 1.2138 0.9041–1.6295 0.1973
R
1 vs. 0 1.405 0.984–2.006 0.0613
CA 19-9
≥ 114 vs. < 114 kU/L 1.1385 0.8459–1.5323 0.3921
Lymph node-ratio
≥ 0.2 vs. < 0.2 1.4942 1.0995–2.0306 0.0103
UICC, Union for International Cancer Control; CI, confidence interval;
RR, relative risk; SII, systemic immune-inflammation index
J Gastrointest Surg
the prognostic capacity of SII, NLR, and PLR, our results
were consistent with those of Chawla et al., revealing that
preoperative SII, but not NLR and PLR, is an independent
prognostic factor for OS in patients with resectable
PDAC.43 Recently, Haldar and Ben-Eliyahu critically
discussed the impact of perioperative β-adrenergic block-
ade and COX2 inhibition on cancer outcomes.45 Thus, pa-
tients with resectable PDAC who have elevated preopera-
tive SII might benefit from anti-inflammatory and/or anti-
immunotherapy prior and after surgery.
Even though the results of the present study demonstrate that
the SII is an independent prognostic factor in patients with
PDAC undergoing resection, it has several limitations.
Although the patients were prospectively entered into a database,
a retrospective analysis was performed with a selection bias by
the availability of complete blood cell count before surgery in
daily practice. The cohort represents the experience of one center
that needs to be validated by external cohort from another center.
There are no consensual cutoff values for inflammation
indices. The majority of studies determine individual cutoff
levels by their relevance and significance, showing a signifi-
cant prediction of survival when applied to the same patients’
cohort. As a result, there is a wide range of cutoff values for
these indices. However, the present study demonstrated that
the SII provided the strongest survival prediction compared to
NLR and PLR in patients with PDAC undergoing surgery.
Emphasis should be given to determine significant cutoff
levels for inflammatory indices that stay valid when applied
to independent cohorts of patients.
The administration of different neo-/adjuvant chemothera-
py regimens and changing policies of treating patients with
borderline disease during the study period may have influ-
enced the study result. However, it reflects the real-world sit-
uation and patients included in the study were treated with
standard regimens that were available at the respective period.
We did not analyze the differences of prognostic strength of
SII during different time intervals reflecting variations in neo-/
adjuvant chemotherapy regimens. However, we could proof
the prognostic value of SII for the entire observation period,
regardless neoadjuvant treatment was administered or not. We
admit that in order to draw representative conclusions for the
association between inflammatory activity and prognosis in
patients undergoing neoadjuvant treatment, a cohort with little
variations in neoadjuvant regimens should be analyzed.
High and low SII was equally distributed in most of the
items characterizing the study cohort. However, resection
rates, CA19-9 and bilirubin blood concentrations were differ-
ent between patients with high and low inflammatory activity.
The difference of resection rates interesting observation that
needs to be addressed by further studies as it may represent an
important factor for treatment decision. There is evidence that
tumor invasion initiates host inflammatory response and one
could argue that the extent of tumor cell infiltration into the
mesopancreatic compartment both stimulates inflammatory
activity and influences the likelihood of complete resection.
Similarly, CA19-9, serves as a surrogate marker of tumor bur-
den and thereby associated with inflammation.
Conclusion
In summary, the present study shows that preoperative SII is
an independent predictor of OS in patients with PDAC under-
going pancreatic resection that is superior to NLR and PLR.
Measurement of SII is easily applicable and of low cost.
Patients with preoperatively elevated SII might benefit from
anti-inflammatory and/or anti-immunotherapy.
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